Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Total and Active Ghrelin Levels
研究概览
简要总结
The purpose of this study is to learn more about how insulin resistance (inability to process glucose correctly resulting in mildly elevated glucose levels) affects the hormone ghrelin.
详细描述
Insulin resistance suppresses fasting ghrelin levels and impairs postprandial ghrelin suppression. Improved insulin sensitivity with a thiazolidinedione will raise ghrelin levels, enhance meal-related suppression, but not change the ratio of total to active ghrelin or result in an alteration of ghrelin structure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 to 80, weight stable for at least 3 months
- •At lifetime maximal body weight and impaired glucose tolerance (ICT) by the World Health ORganization criteria:
- •fasting plasma glucose level of 100- 125mg/dL or
- •plasma glucose level between 140 to 149mg/dL following a 75gram oral glucose load
排除标准
- •Actively losing weight
- •Alcohol consumption > 2 drinks/day
- •Prescription drug use
- •Recreational drug use
- •Type 2 Diabetes
- •Conditions that contraindicate treatment with pioglitazone such as CHF, impaired liver or kidney function or known sensitivity to pioglitazone
研究组 & 干预措施
Placebo
Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
干预措施: placebo (Drug)
pioglitizone
Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
干预措施: pioglitazone (Drug)
结局指标
主要结局
Total and Active Ghrelin Levels
时间窗: 0 and 3 months
The primary outcome of this study will be the comparison of ghrelin suppressibility (total and acylated) in response to meals obese subjects before and after 3-months therapy with a thiazolidinedione.
次要结局
未报告次要终点
研究者
Jonathan Purnell
Prinicipal Investigator
Oregon Health and Science University